Parsortix CTCs used for Brain Cancer detection

AI SummaryClose X

CelLBxHealth plc announced that an independent, peer-reviewed study published in JCO Precision Oncology supports the use of its Parsortix platform for glioblastoma (GBM) detection and monitoring. The study found that a threshold of greater than 4 circulating tumor cells (CTCs) per 5 mL of blood could distinguish GBM patients from healthy controls with 80% sensitivity and 77.3% specificity, and that Parsortix-enriched CTCs reflected matched tumor genomics. These findings align with CelLBxHealth's own research and suggest potential for a minimally invasive liquid biopsy approach in GBM diagnosis and monitoring, particularly in differentiating tumor recurrence from treatment-related changes, as radionecrosis and lymphoma samples yielded no detectable CTCs.

Disclaimer*

UK 100

Latest directors dealings